Overall, the combination of reduced operational costs, faster market access, and potential expansion into new markets positions OncoSil Medical Ltd favorably for increased revenue generation from its OncoSil™ device. The ability to deliver targeted treatment directly to pancreatic tumors while combining it with chemotherapy provides a compelling value proposition that could attract more healthcare providers and patients alike.In summary, MDR approval is expected to significantly boost OncoSil’s revenue by streamlining operations, reducing costs, accelerating market access in Europe and potentially Australia, thereby enhancing commercial success.
OSL Price at posting:
0.6¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)